Plasma MicroRNA for Prediction of Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-13

Study Completion Date

2022-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

100 patients with diagnosed HCV were evaluated by clinical and ultrasound examination and were categorized as uncomplicated HCV (n=22) and complicated HCV (n=78). All patients were evaluated for hepatosteatosis and liver fibrosis using the computerized hepatorenal index, the hepatic steatosis index, aspartate aminotransferase (AST)/platelet count index (APRI) and the Fibrosis-4 (FIB-4) scores. Blood samples were obtained for estimation of serum levels of liver function tests and plasma levels of microRNA 21 and 126.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of microRNAs as a Diagnostic Tool for HCV-related Hepatocellular Carcinoma

NCT03429530

miRna in HCC

UNKNOWN

Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma

NCT02507882

HCV Infection ( Genotype 4)

UNKNOWN NA

Screening for Liver Cancer With CT vs. Ultrasound in Patients With Advanced Liver Disease

NCT01350167

Cirrhosis End Stage Liver Disease Hepatitis C

UNKNOWN NA

The Role of Long Non-coding RNAs WRAP53 and UCA-1 as Potential Biomarkers in Diagnosis of Hepatocellular Carcinoma

NCT05088811

Hepatocellular Carcinoma Liver Cirrhosis Diagnoses Disease

UNKNOWN

Micro RNA Levels in NAFLD

NCT04574557

Non-Alcoholic Fatty Liver Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Complicated HCV

Blood Sampling

Intervention Type BIOLOGICAL

Blood sampling under a complete aseptic conditions

Non Complicated HCV

Blood Sampling

Intervention Type BIOLOGICAL

Blood sampling under a complete aseptic conditions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood Sampling

Blood sampling under a complete aseptic conditions

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Complicated hepatitis C by HCC
* Complicated hepatitis C by liver cirrhosis
* Complicated hepatitis C by steatohepatitis
* uncomplicated hepatitis C

Exclusion Criteria

* pre-portal fibrosis secondary to previous bilharzial disease
* pre-portal fibrosis secondary to alcoholic fatty liver
* The presence of hepatic malignancy other than HCC
* decompensated cirrhosis
* hepatorenal failure
* hepatic manifestations of congestive heart failure.

Minimum Eligible Age

31 Years

Maximum Eligible Age

67 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No